To investigate the efficacy and assess the safety of dual C therapy (CGMS combined with CSII) in the treatment of primary severe type 2 diabetes mellitus (T2DM). In this paper, 100 newly diagnosed severe type 2 diabetes patients admitted to our hospital from January 2020 to December 2021 were selected and divided into the control group (multiple subcutaneous insulin injections+finger tip blood glucose monitoring) and the observation group (double C therapy) with 50 cases each. The general information, blood glucose reaching time, blood glucose drift, insulin dosage, blood glucose, blood lipid level, fasting glucose (FPG), blood glucose 2h after meal (2hPG) The levels of hemoglobin (HbAlc), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and the therapeutic effect. In the observation group, the time taken to reach the blood glucose standard was recorded as 5.36±1.04d, shorter than that of the control group as 7.64±1.11d (P<0.05), and the blood glucose drift was recorded as 7.32±1.54cd mmol/L and insulin dosage was recorded as 0.65±0.08U/kg, both better than that of the control group as 5.17±1.03cd mmol/L, 0.51±0.02U/kg (P<0.05). 0.02 U/kg in the control group (P < 0.05); after treatment, FPG in the observation group was measured as 6.22 ± 0.04) mmol/L, 2hPG was measured as (9.52 ± 1.14) mmol/L, and HbAlc was (6.11 ± 0.65) %, which were better than the corresponding levels in the control group (P<0.05). The TC, TG, and LDL-C levels in this group were [(4.01±0.23) mmol/L, (1.56±0.44) mmol/L, and (3.01±0.23) mmol/L], respectively, all of which were lower than those in the control group (all P<0.05). ALT, CRE, and BUN were found to be comparable between the two groups before and after treatment (P>0.05); the overall effective rate was higher in the observation group (98.00% vs. 86.00%) and the incidence of hypoglycemia was lower in the observation group (0.2% vs. 18.00%) compared with the control group(P<0.05). The combination of CGMS and CSII in T2DM can improve the effect of blood glucose control, reduce the amount of insulin used to treat patients, shorten the time of reaching the standard of blood glucose, and reduce the incidence of hypoglycemia.

Liping Chen, Xiuyu Tian, Jun Guo. Efficacy and Safety of CGMS Combined with Insulin Pump CSII in the Treatment of Newly Diagnosed Severe Type 2 Diabetes. International Journal of World Medicine (2023), Vol. 4, Issue 3: 93-102. https://doi.org/10.38007/IJWM.2023.040311.

[1] Yang Chunjie, Cui Qi, Zhang Shuai, et al Sequential treatment of newly diagnosed type 2 diabetes with insulin pump enhancement as the core. Chinese Journal of Gerontology, 2021,41 (5): 941-945

[2] Zhang Pengxiang, Zeng Lin, Meng Lu, et al New progress in new target drugs for treatment of type 2 diabetes. Chinese Journal of General Practice, 2022,25 (20): 2551-2557

[3] Lv Dan, Liu Xiuling, Shi Yanping, et al Comparison of the efficacy and safety of two short-term insulin intensive treatment schemes for type 2 diabetes patients with different HbA1c levels. Shandong Medicine, 2021, 61 (14): 45-47

[4] Lv Fang, Cai Xiaoling, Ji Linong Meta analysis of dose adjustment schemes for multiple subcutaneous insulin injection intensive treatment in patients with type 2 diabetes. Chinese Journal of diabetes, 2021,29 (5): 353-361

[5] Shi Xue, Chen Yan, Zhang Yan, et al Comparison of clinical efficacy of intensive treatment of newly diagnosed type 2 diabetes with gligliptin combined with CSII and CSII alone. Chinese Journal of Gerontology, 2017, 37 (12): 2952-2953

[6] Cheng Liang, Hu Yun, Zhong Yi, etc Effect of intensive insulin therapy on regulatory T cells in peripheral blood of patients with type 2 diabetes. Chinese Journal of diabetes, 2021,29 (10): 727-732

[7] Zhou Jianhua, Li Xiaohua, Bei Pengjian, etc The correlation between blood glucose fluctuation and oxidative stress, inflammation and monocyte autophagy in early type 2 diabetic nephropathy. Chinese Journal of Gerontology, 2021,41 (1): 32-36

[8] Lin Jinxiang, Chen Xiaoyan, Yan Jianhua, et al Study on the accuracy and safety of a new remote dynamic blood glucose monitoring system. International Journal of Endocrinology and Metabolism, 2021,41 (2): 105-109132

[9] Guo Fengxian, Ma Xiaoxin, Hu Guangqian, et al The effect of Omaha system intervention mode on type 2 diabetes patients receiving real-time dynamic glucose monitoring combined with continuous subcutaneous insulin injection. Journal of Nurse Training, 2020, 35 (22): 2039-2043

[10] Diabetes Branch of Chinese Medical Association Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020 Edition). Chinese Journal of diabetes, 2021,13 (4): 315-409

[11] Chen Yuying, Li Xiaodong, Tang Yunzhao, et al Meta analysis of the clinical efficacy of different doses of cagelin combined with metformin in the treatment of type 2 diabetes. Chinese General Medicine, 2022,25 (15): 1888-18961905

[12] Shen Liping, Ying Lei, Yu Lilei, et al Clinical efficacy of Bailing tablet combined with conventional treatment in elderly patients with early diabetes nephropathy. Chinese patent medicine, 2021,43 (10): 2926-2928

[13] Chen Shuang, Yang Tao, Gu Xuan Diagnosis and immunotherapy of type 1 diabetes. International Journal of Endocrinology and Metabolism, 2021,41 (6): 578-582

[14] Guo Lixin Review of Major Annual Progress in diabetes in 2021. Chinese Journal of diabetes, 2022, 14 (1): 1-8

[15]Refardt J. Diagnosis and differential diagnosis of diabetes insipidus: Update.  Best Pract Res Clin Endocrinol Metab.  2020,34(5):101398.

[16]Christ-Crain M, Winzeler B, Refardt J. Diagnosis and management of diabetes insipidus for the internist: an update.  J Intern Med. 2021,290(1):73-87.

[17] Zhang Yawen, Zhang Qiongyue, Tao Junjun, etc Related factors of hypoglycemia attack in type 2 diabetes patients based on dynamic glucose monitoring system. Journal of Fudan University (Medical Edition), 2021,48 (5): 637-647

[18] He Qiong, Bo Jiaqi, Zhang Jiaxin, etc Application of scanning glucose monitoring technology in blood glucose management mode of type 2 diabetes patients. International Journal of Endocrinology and Metabolism, 2021,41 (4): 348-351371

[19] Yang Dan, Zhang Yan, Zhang Yuanyuan, etc Effect of dynamic blood glucose monitoring on glucose and lipid metabolism and self-management ability of type 2 diabetes patients. Nursing Research, 2022,36 (3): 528-530

[20] Qi Jinying, Zhang Yue, Chen Yajing, et al Evaluation of the effect of dynamic blood glucose monitoring on health education for patients with type 2 diabetes. China Health Education, 2020, 36 (7): 664-666677

[21]Adolfsson P, Ziegler R, Hanas R. Continuous subcutaneous insulin infusion: Special needs for children.  Pediatr Diabetes.  2017,18(4):255-261.

[22]Cahn A, Roitman E, Aharon-Hananel G, Raz I. Continuous subcutaneous insulin infusion-an opportunity for better care but not a "magic pill".  Endocrine.  2017 Apr; 56(1):4-6.

[23] Wu Yanli, Li Jianhong, Shen Tao, et al Analysis of blood glucose monitoring status and influencing factors of type 2 diabetes patients in Chaoyang District, Beijing. China Health Education, 2019, 35 (7): 601-606

[24]Martens T, Beck RW, Bailey R,et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.  JAMA.  2021,325(22):2262-2272.

[25] Mo Chunrong, Mo Jianxun, Meng Wenwen, et al Application and nursing of real-time dynamic blood glucose monitoring in type 2 diabetes. Chinese Journal of Practical Nursing, 2017,33 (z1): 18-19

[26]Cappon G, Vettoretti M, Sparacino G,et al. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications.  Diabetes Metab J. 2019,43(4):383-397.

[27] Ji Shu, Zhang Aizhi, Yan Su Application of dynamic glucose monitoring system combined with continuous subcutaneous insulin infusion with insulin pump in patients with type 2 diabetes. Qilu Journal of Nursing, 2021,27 (19): 68-70